Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BGB-43395

Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) · developed by BeOne Medicines

Phase 3 Most advanced trial
ONC Developer
1 Registered trials

What is BGB-43395?

BGB-43395 is an orally bioavailable, selective inhibitor of cyclin-dependent kinase 4 (CDK4). By blocking CDK4-mediated phosphorylation of retinoblastoma protein early in G1, it prevents the G1-S transition, arrests the cell cycle and suppresses tumor cell proliferation. It is studied in HR-positive, HER2-negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
cyclin-dependent kinase 4 (CDK4)
Mechanism
Inhibitor of cyclin-dependent kinase 4 (CDK4)
Pathways
cell cycle G1-S transition, Rb phosphorylation
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07492641 Phase 3 HR+/HER2- Breast Cancer Recruiting ONC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HR+/HER2- Breast Cancer

Other drugs acting on CDK4

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BGB-43395

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.